CoChat

Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Open access
Bolignano, Davide, Cabassi, Aderville, Fiaccadori, Enrico, Ghigo, Ezio, Pasquali, Renato, Peracino, Andrea, Peri, Alessandro, Plebani, Mario, Santoro, Antonio, Settanni, Fabio, Zoccali, Carmine · 2014 · Clinical Chemistry and Laboratory Medicine (CCLM)
Cited by 123

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

Arginine vasopressin (AVP) plays a key role in many physiologic and pathologic processes. The most important stimulus for AVP release is a change in plasma osmolality. AVP is also involved in the response and adaptation to stress. Reliable measurement of AVP is hindered by several factors. Over 90% of AVP is tightly bound to platelets, and its estimation is influenced by the number of platelets, incomplete removal of platelets or pre-analytical processing steps. Copeptin (CTproAVP), a 39-aminoacid glycopeptide, is a C-terminal part of the precursor pre-provasopressin (pre-proAVP). Activation of the AVP system stimulates CTproAVP secretion into the circulation from the posterior pituitary gland in equimolar amounts with AVP. Therefore CTproAVP directly reflects AVP concentration and can be used as a surrogate biomarker of AVP secretion. In many studies CTproAVP represents AVP levels and its behavior represents changes in plasma osmolality, stress and various disease states, and shows some of the various physiologic and pathophysiologic conditions associated with increased or decreased AVP. Increased CTproAVP concentration is described in several studies as a strong predictor of mortality in patients with chronic heart failure and acute heart failure. Autosomal polycystic kidney disease (ADPKD) patients have both central and nephrogenic defects in osmoregulation and CTproAVP balance. A possibility raised by these clinical observations is that CTproAVP may serve to identify patients who could benefit from an intervention aimed at countering AVP.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1515/cclm-2014-0379

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 123

Metadata

Authors
Bolignano, D., Cabassi, A., Fiaccadori, E., Ghigo, E., Pasquali, R., Peracino, A., Peri, A., Plebani, M., Santoro, A., Settanni, F., & Zoccali, C.
Venue
Clinical Chemistry and Laboratory Medicine (CCLM)
Published
2014-01-01
Volume
52
Issue
10
Pages
1447-56
ISSN
  • 1434-6621 (ISSN-L)
  • 1437-4331
OpenAlex
W2143195083
Cited by
123
References
11
FWCI
7.51
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. https://app.cochat.ai/papers/10.1515/cclm-2014-0379
The paper
Bolignano, D., Cabassi, A., Fiaccadori, E., Ghigo, E., Pasquali, R., Peracino, A., Peri, A., Plebani, M., Santoro, A., Settanni, F., & Zoccali, C. (2014). Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clinical Chemistry and Laboratory Medicine (CCLM). https://doi.org/10.1515/cclm-2014-0379

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.